达仁堂: 达仁堂2025年第三次监事会决议公告

Core Points - The company held its third supervisory board meeting of 2025 on August 13, 2025, with all three supervisors present, confirming compliance with the company's articles of association [1][2] - The supervisory board approved the company's 2025 semi-annual report, affirming that it accurately reflects the company's operational management and financial status [1] - The board also approved the special report on the storage and actual use of raised funds for the first half of 2025 [1] - A risk assessment report regarding Tianjin Pharmaceutical Group Finance Co., Ltd. was also reviewed and approved by the board [1] Summary by Sections Meeting Details - The meeting was convened on August 13, 2025, with all three supervisors present, meeting the requirements of the company's regulations [1] Semi-Annual Report - The supervisory board reviewed and confirmed the accuracy of the 2025 semi-annual report, ensuring it complies with internal management systems and exchange regulations [1] Fund Usage Report - The board approved the special report on the storage and actual use of raised funds, with unanimous agreement from all supervisors [1][2] Risk Assessment - A risk assessment report concerning Tianjin Pharmaceutical Group Finance Co., Ltd. was discussed and approved by the supervisory board [1]